Axogen, Inc.

AXGN ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-15.7M $-10.0M $-21.7M $-28.9M $-27.0M $-23.8M $-29.1M $-22.4M
Depreciation & Amortization $6.7M $6.5M $4.2M $2.8M $2.7M $1.5M — —
Depreciation $6.7M $6.5M $4.2M $2.8M $2.7M $1.5M $933.0K $774.0K
Amortization $315.0K $267.0K $273.0K $265.0K $202.0K $153.0K $123.0K $77.0K
Stock-Based Compensation $30.1M $15.9M $14.4M $15.6M $10.9M $8.5M $10.3M $7.6M
Net Cash from Operating Activities $812.0K $4.5M $-5.7M $-16.1M $-13.4M $-9.6M $-19.9M $-17.9M
Investing Activities
Capital Expenditures $3.7M $3.1M $13.9M $20.1M $27.8M $21.9M $4.7M $6.3M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-5.3M $-10.3M $19.3M $-3.2M $-23.6M $-17.0M $27.3M $-98.2M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $10.5M $2.3M $2.0M $1.8M $20.5M $40.5M $4.0M $109.8M
Net Change in Cash $6.0M $-3.5M $15.5M $-17.5M $-16.6M $13.9M $11.4M $-6.2M
Free Cash Flow $-2.9M $1.4M $-19.6M $-36.1M $-41.2M $-31.5M $-24.5M $-24.1M
← Newer Page 1 of 2 Older →